KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Summary of Research: Apremilast Improves Skin Outcomes in Pediatric Plaque Psoriasis of Shorter Disease Duration: 52-Week Results from the SPROUT Phase 3 Trial.

Richard G Langley, Lisa Arkin, Loretta Fiorillo, Lawrence F Eichenfield, Mark Lebwohl, Bruce Strober, Michael Sticherling, Lisa Swanson, Georgios Kokolakis, Siddharth Chaudhari, Cynthia Deignan, Zuoshun Zhang, Amy S Paller

Dermatol Ther (Heidelb) 16(5) 2229-2232

PMID42133282
PMCIDPMC13219672
DOI10.1007/s13555-026-01714-0
发表日期2026-05-14
摘要

摘要

This is a summary of the original article "Apremilast improves skin outcomes in pediatric plaque psoriasis of shorter disease duration: 52-week results from the SPROUT phase 3 trial". Enrolled patients were aged 6-17 years with moderate to severe plaque psoriasis (PsO) inadequately controlled by, or inappropriate for, topical therapy (NCT03701763). Patients were randomized to apremilast or placebo for 16 weeks, after which all patients transitioned to apremilast through 52 weeks. The efficacy of apremilast was assessed by disease duration at baseline (shorter, < 2 years; medium, ≥ 2 to < 5 years; longer, ≥ 5 years). In this post hoc analysis, patients had generally similar baseline characteristics across disease durations. At week 16, patients receiving apremilast vs placebo experienced numerically greater improvements in most skin clearance outcomes across all disease durations, particularly in patients with disease duration < 2 years. Through week 52, patients experienced numerical improvements across all disease durations, with the most pronounced efficacy in patients with disease duration < 5 years. These findings suggest early intervention with a systemic therapy such as apremilast in pediatric patients with moderate to severe PsO may mitigate disease burden.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。